Clinical Trials on Hepatic Insufficiency in United States

Total 4357 results

The Cleveland Clinic
American College of Gastroenterology

Withdrawn

Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis

End Stage Liver Disease | Cirrhosis | Ascites | Hypotension

United States
Sanofi

Completed

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

United States, Belgium
Bausch Health Americas, Inc.

Active, not recruiting

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3131)

Hepatic Encephalopathy

United States, Australia, Canada, Puerto Rico
UCB Biopharma S.P.R.L.

Terminated

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Impaired Hepatic Function | Healthy Study Participants

United States
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (HALT-HE)

Hepatic Encephalopathy | Cirrhosis

United States
Baxter Healthcare Corporation
Gambro Lundia AB; 2ConduCT; G.E.M. mbh Meerbusch; DatInf

Completed

Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure (RELIEF)

Liver Failure

Spain, Denmark, Germany, Austria, France, Belgium, Italy, Switzerland, United Kingdom
Bausch Health Americas, Inc.

Completed

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Hepatic Encephalopathy | Cirrhosis

United States
King's College Hospital NHS Trust
King's College London

Completed

Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy (RIFSYS)

Liver Cirrhosis | Hepatoencephalopathy, Early Fatal Progressive

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer
ViroPharma

Completed

Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

Hepatic Insufficiency | Hepatitis C

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Healthy | Hepatic Impairment

United States
Nektar Therapeutics

Completed

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

United States
National Institutes of Health Clinical Center (CC)

Completed

Study of New Software Used During Ablations

Liver Cancer | Hepatic Cancer | Neoplasms, Liver | Hepatic Neoplasms

United States
Massachusetts General Hospital

Terminated

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

End Stage Liver Disease | Hepatitis C

United States
Sanofi

Completed

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

Hepatic Function Abnormal

United States, Germany
St George's, University of London
King's College Hospital NHS Trust

Recruiting

S100A8/A9 and Innate Immunity in Liver Disease

Infections | Cirrhosis, Liver | Ascites Hepatic | Immune Suppression | Liver Failure, Acute on Chronic

United Kingdom
Taiho Oncology, Inc.

Completed

Evaluating Patients With Impaired Hepatic Function

Impaired Hepatic Function

United States
Massachusetts General Hospital

Recruiting

LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease (LiverPAL)

Cirrhosis | Cirrhosis, Liver | End Stage Liver DIsease | Liver Disease Chronic | Advanced Cirrhosis

United States
St. Jude Children's Research Hospital

No longer available

Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

Hepatic Veno-occlusive Disease

United States
OSF Healthcare System

Completed

Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome

Hepatic Encephalopathy | Hepatitis C | Cirrhosis | Nonalcoholic Steatohepatitis

United States
University of Pennsylvania
Pennsylvania Department of Health

Recruiting

Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease

Cirrhosis, Liver | Muscle Loss | Physical Inactivity | End Stage Liver DIsease | Symptoms and Signs

United States
Indiana University
Malaysia Palm Oil Board

Recruiting

Tocotrienol Against the Progression of End Stage Liver Disease

End Stage Liver Disease | NASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver Disease

United States
University of Colorado, Denver

Active, not recruiting

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

Obesity | Acute Kidney Injury | End Stage Liver DIsease

United States
William Lee
Medical University of South Carolina; National Institute of Diabetes and Digestive... and other collaborators

Completed

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF)

Acute Liver Failure | Acute Liver Injury

United States
Basilea Pharmaceutica

Active, not recruiting

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.

Hepatic Impairment

United States
Galmed Research and Development, Ltd.

Enrolling by invitation

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Indiana University

Completed

Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

Hepatic Disease

United States
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Midwestern Regional Medical Center

Terminated

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Cancer | Hepatic Injury

United States
Samsung Electronics

Terminated

Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting

Hepatic Disease

United States
Cephalon

Completed

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

Hepatic Impairment

United States
Alkermes, Inc.

Completed

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Wockhardt

Completed

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Hepatic Impairment

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
Hutchmed

Completed

Fruquintinib Hepatic Impairment Study

Hepatic Impairment

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib Hepatic Impairment Trial

Hepatic Impairment

United States
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

United States
Pfizer

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Hepatic Impairment

United States
Intercept Pharmaceuticals

Completed

Hepatic Impairment Trial of Obeticholic Acid

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Hepatic Impairment

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Melinta Therapeutics, Inc.

Completed

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

Hepatic Impairment

United States
Biogen

Completed

BG9928 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Pfizer

Completed

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Allergan

Completed

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Hepatic Impairment

United States
PTC Therapeutics

Completed

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

Hepatic Impairment

United States

Clinical Trials on Hepatic Insufficiency in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations